Istodax

Phase 1Small molecule

Bristol-Myers Squibb

Istodax is one of 79 small molecule programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Cutaneous T-Cell LymphomaActive, not recruiting

LymphomaPreclinical

Active, not recruiting

Cutaneous T-Cell LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Oncaspar

SServier

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Tafasitamab

Incyte

Preclinical

7 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—10

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cutaneous T-cell lymphoma1 trial

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

Completed·UUnknown Sponsor·Phase 1·NCT01902225·24 enrolled

Lymphoma1 trial

ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT03742921·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Istodax. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Istodax compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Istodax. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Bristol-Myers Squibb

Istodax

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cutaneous T-cell lymphoma1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News